Bioengineering the liver: Scale-up and cool chain delivery of the liver cell biomass for clinical targeting in a bioartificial liver support system

BioResearch Open Access

Volumn 2, Issue 1, 2013, Pages 1-11

  Erro, Eloy ^a   Bundy, James ^a   Massie, Isobel ^a   Chalmers, Sherri Ann ^a   Gautier, Aude ^a   Gerontas, Spyridon ^b   Hoare, Mike ^b   Sharratt, Peter ^c   Choudhury, Sarah ^a   Lubowiecki, Marcin ^a   Llewellyn, Ian ^a   Legallais, Cécile ^d   Fuller, Barry ^e   Hodgson, Humphrey ^a   Selden, Clare ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

alginate encapsulation; fluidized bed bioreactor; HepG2 cells

Indexed keywords

ALGINIC ACID; MESSENGER RNA;

ARTICLE; BIOARTIFICIAL LIVER; BIOARTIFICIAL LIVER SUPPORT SYSTEM; BIOENGINEERING; BIOMASS; CELL CONTACT; CELL DENSITY; CELL ENCAPSULATION; CELL FUNCTION; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; ENVIRONMENTAL TEMPERATURE; FLUIDIZED BED REACTOR; GROWTH CURVE; HUMAN; HUMAN CELL; LIVER; LIVER CELL; LIVER REGENERATION; LIVER SUPPORT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCALE UP; SPHEROID CELL;

EID: 85053510655     PISSN: None     EISSN: 21647860     Source Type: Journal    
DOI: 10.1089/biores.2012.0286     Document Type: Article

References (68)

1. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947-954.
2. Carpentier B, Gautier A, Legallais C. Artificial and bioartificial liver devices: present and future. Gut. 2009;58: 1690-1702.
3. Gerlach J, Kloppel K, Schauwecker HH, et al. Use of hepatocytes in adhesion and suspension cultures for liver support bioreactors. Int J Artif Organs. 1989;12:788-792.
4. Liu JJ, Chen BS, Tsai TF, et al. Long term and large-scale cultivation of human hepatoma Hep G2 cells in hollow fiber bioreactor. Cultivation of human hepatoma Hep G2 in hollow fiber bioreactor. Cytotechnology. 1991;5:129-139.
5. Matsushita T, Ijima H, Koide N, et al. High albumin production by multicellular spheroids of adult rat hepatocytes formed in the pores of polyurethane foam. Appl Microbiol Biotechnol. 1991;36:324-326.
6. Shatford RA, Nyberg SL, Meier SJ, et al. Hepatocyte function in a hollow fiber bioreactor: a potential bioartificial liver. J Surg Res. 1992;53:549-557.
7. Rozga J, Williams F, Ro MS, et al. Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells. Hepatology. 1993;17:258-265.
8. Bader A, Knop E, Fru? hauf N, et al. Reconstruction of liver tissue in vitro: geometry of characteristic flat bed, hollow fiber, and spouted bed bioreactors with reference to the in vivo liver. Artif Organs. 1995;19:941-950.
9. Naruse K, Sakai Y, Nagashima I, et al. Comparisons of porcine hepatocyte spheroids and single hepatocytes in the non-woven fabric bioartificial liver module. Int J Artif Organs. 1996;19:605-609.
10. Flendrig LM, la Soe JW, Jo?rning GG, et al. In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates. J Hepatol. 1997;26:1379-1392.
11. Ohshima N, Yanagi K, Miyoshi H. Packed-bed type reactor to attain high density culture of hepatocytes for use as a bioartificial liver. Artif Organs. 1997;21:1169-1176.
12. Matsuura T, Kawada M, Hasumura S, et al. High density culture of immortalized liver endothelial cells in the radial-flow bioreactor in the development of an artificial liver. Int J Artif Organs. 1998;21:229-234.
13. Busse B, Gerlach JC. Bioreactors for hybrid liver support: historical aspects and novel designs. Ann NY Acad Sci. 1999; 875:326-339.
14. Shito M, Kim NH, Baskaran H, et al. In vitro and in vivo evaluation of albumin synthesis rate of porcine hepatocytes in a flat-plate bioreactor. Artif Organs. 2001;25:571-578.
15. Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology. 1996;24:1446-1451.
16. Starzl TE, Putnam CW, Groth CG, et al. Alopecia, ascites, and incomplete regeneration after 85 to 90 per cent liver resection. Am J Surg. 1975;129:587-590.
17. Khalil M, Shariat-Panahi A, Tootle R, et al. Human hepatocyte cell lines proliferating as cohesive spheroid colonies in alginate markedly upregulate both synthetic and detoxificatory liver function. J Hepatol. 2001;34:68-77.
18. Selden C, Khalil M, Hodgson H. Three dimensional culture upregulates extracellular matrix protein expression in human liver cell lines - a step towards mimicking the liver in vivo? Int J Artif Organs. 2000;23:774-781.
19. Demetriou AA, Brown RS Jr, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg. 2004;239: 660-667.
20. Fruhauf JH, Mertsching H, Giri S, et al. Porcine endogenous retrovirus released by a bioartificial liver infects primary human cells. Liver Int. 2009;29:1553-1561.
21. Baquerizo A, Mhoyan A, Kearns-Jonker M, et al. Characterization of human xenoreactive antibodies in liver failure patients exposed to pig hepatocytes after bioartificial liver treatment: an ex vivo model of pig to human xenotransplantation. Transplantation. 1999;67:5-18.
22. Baquerizo A, Mhoyan A, Shirwan H, et al. Xenoantibody response of patients with severe acute liver failure exposed to porcine antigens following treatment with a bioartificial liver. Transplant Proc. 1997;29:964-965.
23. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 1980;209:497-499.
24. Massie I, Selden C, Hodgson H, et al. Cryopreservation of encapsulated liver spheroids for a bioartificial liver: reducing latent cryoinjury using an ice nucleating agent. Tissue Eng Part C. 2011;17:765-774.
25. David B, Barbe L, Barthes-Biesel D, et al. Mechanical properties of alginate beads hosting hepatocytes in a fluidized bed bioreactor. Int J Artif Organs. 2006;29:756-763.
26. David B, Dore E, Jaffrin MY, et al. Mass transfers in a fluidized bed bioreactor using alginate beads for a future bioartificial liver. Int J Artif Organs. 2004;27:284-293.
27. Legallais C, Dore E, Paullier P. Design of a fluidized bed bioartificial liver. Artif Organs. 2000;24:519-525.
28. Legallais C, Jaffrin MY. A feasibility study of a filtration type autotransfusion device. J Biomed Eng. 1993;15:143-147.
29. Spackman DH, Stein WH, Moore S. Automatic recording apparatus for use in the chromatography of amino acids. Anal Chem. 1958;30:1190-1206.
30. Blackard WG, Clore JN, Powers LP. A stimulatory effect of FFA on glycolysis unmasked in cells with impaired oxidative capacity. Am J Physiol. 1990;259:E451-E456.
31. Carpentier B, Gautier A, Legallais C. Artificial and bioartificial liver devices: present and future. Gut. 2009;58:1690-1702.
32. Rifai K, Kribben A, Gerken G, et al. Extracorporeal liver support by fractionated plasma separation and adsorption (Prometheus) in patients with acute-on-chronic liver failure (Helios Study): a prospective randomized controlled multicenter study. J Hepatol. 2010;52:S3.
33. Banares R, Nevens F, Larsen FS, et al. Extracorporeal liver support with the molecular adsorbent recirculating system (MARS) in patients with acute-on-chronic liver failure (AOCLF). The Relief Trial. J Hepatol. 2010;52:S459-S460.
34. Menard M, Dusseault J, Langlois G, et al. Role of protein contaminants in the immunogenicity of alginates. J Biomed Mater Res B Appl Biomater. 2010;93:333-340.
35. Klock G, Pfeffermann A, Ryser C, et al. Biocompatibility of mannuronic acid-rich alginates. Biomaterials. 1997;18:707-713.
36. Coward SM, Selden C, Mantalaris A, et al. Proliferation rates of HepG2 cells encapsulated in alginate are increased in a microgravity environment compared with static cultures. Artif Organs. 2005;29:152-158.
37. Coward SM, Legallais C, David B, et al. Alginate-encapsulated HepG2 cells in a fluidized bed bioreactor maintain function in human liver failure plasma. Artif Organs. 2009;33:1117-1126.
38. Damelin LH, Coward S, Kirwan M, et al. Fat-loaded HepG2 spheroids exhibit enhanced protection from pro-oxidant and cytokine induced damage. J Cell Biochem. 2007;101:723-734.
39. Selden C, Shariat A, McCloskey P, et al. Three-dimensional in vitro cell culture leads to a marked upregulation of cell function in human hepatocyte cell lines - an important tool for the development of a bioartificial liver machine. Ann NY Acad Sci. 1999;875:353-363.
40. Thu B, Bruheim P, Espevik T, et al. Alginate polycation microcapsules. II. Some functional properties. Biomaterials. 1996;17:1069-1079.
41. Dore E, Legallais C. A new concept of bioartificial liver based on a fluidized bed bioreactor. Ther Apher. 1999;3:264-267.
42. Mavri-Damelin D, Eaton S, Damelin LH, et al. Ornithine transcarbamylase and arginase I deficiency are responsible for diminished urea cycle function in the human hepatoblastoma cell line HepG2. Int J Biochem Cell Biol. 2007;39: 555-564.
43. Bode BP, Souba WW. Modulation of cellular proliferation alters glutamine transport and metabolism in human hepatoma cells. Ann Surg. 1994;220:411-422.
44. Bode BP, Fuchs BC, Hurley BP, et al. Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells. Am J Physiol Gastrointest Liver Physiol. 2002;283:G1062-G1073.
45. Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line HEPG2 with regard to their biotransformation properties. Drug Metab Dispos. 2003;31:1035-1042.
46. Khaoustov VI, Risin D, Pellis NR, et al. Microarray analysis of genes differentially expressed in HEPG2 cells cultured in simulated microgravity: preliminary report. In Vitro Cell Dev Biol Anim. 2001;37:84-88.
47. Shimada M, Yamashita Y, Tanaka S, et al. Characteristic gene expression induced by polyurethane foam/spheroid culture of hepatoma cell line, Hep G2 as a promising cell source for bioartificial liver. Hepatogastroenterology. 2007;54:814- 820.
48. Thomas A, Hodgson HJF, Selden C. Cytochrome P450 activity in HepG2 cells is significantly chemically enhanced and can be maintained in the absence of inducer. BASL 2007;44.
49. Marroquin LD, Hynes J, Dykens JA, et al. Circumventing the crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci. 2007;97:539-547.
50. Nilsson HO, Blom J, Abu Al-Soud W, et al. Effect of cold starvation, acid stress, and nutrients on metabolic activity of Helicobacter pylori. Appl Environ Microbiol. 2002;68:11-19.
51. Bai J, Cederbaum AI. Adenovirus-mediated overexpression of catalase in the cytosolic or mitochondrial compartment protects against cytochrome P450 2E1-dependent toxicity in HepG2 cells. J Biol Chem. 2001;276:4315-4321.
52. Bai JX, Rodriguez AM, Melendez JA, et al. Overexpression of catalase in cytosolic or mitochondrial compartment protects HepG2 cells against oxidative injury. J Biol Chem. 1999;274: 26217-26224.
53. Papp E, Nardai G, Soti C, et al. Molecular chaperones, stress proteins and redox homeostasis. Biofactors. 2003;17:249-257.
54. Patel B, Khaliq A, JarvisEvans J, et al. Hypoxia induces HSP 70 gene expression in human hepatoma (HEP G2) cells. Biochem Mol Biol Int. 1995;36:907-912.
55. Poss KD, Tonegawa S. Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci USA. 1997;94: 10925-10930.
56. Allen JW, Hassanein T, Bhatia SN. Advances in bioartificial liver devices. Hepatology. 2001;34:447-455.
57. Imamura H, Kawasaki S, Shiga J, et al. Quantitative evaluation of parenchymal liver cell volume and total hepatocyte number in cirrhotic patients. Hepatology. 1991;14:448-453.
58. Gerontas S, Farid SS, Hoare M. Windows of operation for bioreactor design for the controlled formation of tissue-engineered arteries. Biotechnol Prog. 2009;25:842-853.
59. Poyck PP, Hoekstra R, van Wijk AC, et al. Functional and morphological comparison of three primary liver cell types cultured in the AMC bioartificial liver. Liver Transpl. 2007; 13:589-598.
60. Mueller D, Tascher G, Mu? ller-Vieira U, et al. In-depth physiological characterization of primary human hepatocytes in a 3D hollow-fiber bioreactor. J Tissue Eng Regen Med. 2011; 5:e207-218.
61. Schmelzer E, Triolo F, Turner ME, et al. Three-dimensional perfusion bioreactor culture supports differentiation of human fetal liver cells. Tissue Eng Part A. 2010;16:2007-2016.
62. Selden C, Erro E, Spearman W, et al. Towards a clinical bioartificial liver machine based on human liver cells. Int J Artif Organs. 2012;35(8):555-587.
63. Matsumoto S. Clinical application of perfluorocarbons for organ preservation. Artif Cells Blood Substit Immobil Biotechnol. 2005;33:75-82.
64. Gioviale MC, Damiano G, Palumbo VD, et al. Pancreatic islets from non-heart-beating donor pig: two-layer preservation method in an in vitro porcine model. Int J Artif Organs. 2011;34:519-525.
65. Hosgood SA, Nicholson ML. The role of perfluorocarbon in organ preservation. Transplantation. 2010;89:1169-1175.
66. Vairetti M, Griffini P, Pietrocola G, et al. Cold-induced apoptosis in isolated rat hepatocytes: protective role of glutathione. Free Radic Biol Med. 2001;31:954-961.
67. Huang H, Salahudeen AK. Cold induces catalytic iron release of cytochrome P-450 origin: a critical step in cold storageinduced renal injury. Am. J Transpl. 2002;2:631-639.
68. Karhumaki P, Tiitinen SL, Turpeinen H, et al. Inhibition of ERK 1/2 activation by phenolic antioxidants protects kidney tubular cells during cold storage. Transplantation. 2007;83: 948-953.